【問題】N engl j med 2000 342 145 153 ?推薦回答
關於「N engl j med 2000 342 145 153」標籤,搜尋引擎有相關的訊息討論:
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on ...。
... ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301.: 。
Renoprotective Effect of the Angiotensin-Receptor ... - NEJM。
Background It is unknown whether either the angiotensin-II–receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of ...。
Major Outcomes in High-Risk Hypertensive Patients Randomized to ...。
... ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med.2000;342:145-153.: tw | tw。
The Heart Outcomes Prevention Evaluation Study - HOPE - Ramipril。
2014年9月22日 · N Engl J Med 2000;342:145-53. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk ...: 。
Reinventing the ACE inhibitors: some old and new implications of ...。
2009年11月13日 · Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153 ...。
Evidence-Based Guidelines for Cardiovascular Disease Prevention ...。
Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum ... N Engl J Med. ... Med. 2000;342:145–153.。
Cardiac Rehabilitation and Secondary Prevention of Coronary Heart ...。
6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000. ... 2000; 342: 145–153.[Published errata in: N Engl J Med. 2000; 342: 1376;N Engl J Med.。
Managing Hypertension Using Combination Therapy - American ...。
2008年5月1日 · N Engl J Med. 2000;342(3):145-153. 34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium ...。
Pharmacologic therapy of heart failure with reduced ejection fraction。
2020年7月6日 · Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145.。
Obesity and Diabetes。
145. 146. 147. 148. Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G for the ... Ann Intern Med 2001;134:1–11. ... N Engl J Med 2000:342:145–153.
常見N engl j med 2000 342 145 153問答
延伸文章資訊Clinical trials of angiotensin-converting enzyme (ACE) inhibitors and ... combination with Ramipr...
... in high-risk patients: results from ONTARGET and TRANSCEND trials ... The Systolic blood Pres...
The ONTARGET (Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial) ...
Large-scale cardiovascular trials traditionally have targeted clinical ... with Ramipril Global E...
The ONTARGET Trial Programme includes the ONTARGET and TRANSCEND studies. In both studies, partic...
The 2008 Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARG...
... Alone and in combination with Ramipril Global Endpoint Trial - ONTARGET ... Trial Sponsor: Bo...
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Tim...
Clinical trials of angiotensin-converting enzyme (ACE) inhibitors and ... combination with Ramipr...
... in high-risk patients: results from ONTARGET and TRANSCEND trials ... The Systolic blood Pres...
The ONTARGET (Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial) ...
Large-scale cardiovascular trials traditionally have targeted clinical ... with Ramipril Global E...
The ONTARGET Trial Programme includes the ONTARGET and TRANSCEND studies. In both studies, partic...
The 2008 Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARG...
... Alone and in combination with Ramipril Global Endpoint Trial - ONTARGET ... Trial Sponsor: Bo...
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Tim...